Mibefradil
From Self-sufficiency
Revision as of 21:23, 18 August 2010 by Edgar181 (Talk) (Removed Category:Acetates; Adding category Category:Methyl esters (using HotCat))
| File:Mibefradil.png | |
| Systematic (IUPAC) name | |
|---|---|
|
(1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl) (methyl)amino)ethyl)-6-fluoro-1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate | |
| Clinical data | |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 116644-53-2 |
| ATC code | C08CX01 (WHO) |
| PubChem | CID 60662 |
| Chemical data | |
| Formula | C29H38FN3O3 |
| Molar mass | 495.63 g/mol[[Script error: No such module "String".]] |
Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers.
It is nonselective.[1]
On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market,[2] due to the potential for drug interactions, some of them serious, which may occur when it is taken together with some other medications.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 30px | This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it. |
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ Letter from Roche Laboratories: http://www.fda.gov/medwatch/SAFETY/1998/poscor.htm
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Calcium channel blockers
- Withdrawn drugs
- Benzimidazoles
- Organofluorides
- Ethers
- Amines
- Methyl esters
- Cardiovascular system drug stubs
- 2Fix
